In other words, the price has increased by $0.0000 from its previous closing price. On the day, 1019804 shares were traded.
Ratios:
For a deeper understanding of Taysha Gene Therapies Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.06. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 01, 2023, Downgraded its rating to Hold and sets its target price to $1.50 from $14 previously.
On January 27, 2023, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $23 to $3.
Goldman Downgraded its Buy to Neutral on November 09, 2022, whereas the target price for the stock was revised from $16 to $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’23 when Manning Paul B bought 100,000 shares for $1.63 per share. The transaction valued at 163,000 led to the insider holds 16,566,667 shares of the business.
Alam Kamran sold 33,000 shares of TSHA for $76,890 on Aug 24 ’23. The Chief Financial Officer now owns 258,042 shares after completing the transaction at $2.33 per share. On Aug 16 ’23, another insider, Manning Paul B, who serves as the 10% Owner of the company, bought 16,466,667 shares for $0.90 each. As a result, the insider paid 14,820,000 and bolstered with 16,466,667 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 500.27M and an Enterprise Value of 417.44M. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.44 while its Price-to-Book (P/B) ratio in mrq is 6.69. Its current Enterprise Value per Revenue stands at 27.02 whereas that against EBITDA is -3.97.
Stock Price History:
Over the past 52 weeks, TSHA has reached a high of $3.89, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is 2.2910, while the 200-Day Moving Average is calculated to be 1.9460.
Shares Statistics:
For the past three months, TSHA has traded an average of 2.81M shares per day and 2.16M over the past ten days. A total of 186.96M shares are outstanding, with a floating share count of 128.60M. Insiders hold about 31.24% of the company’s shares, while institutions hold 62.25% stake in the company. Shares short for TSHA as of Mar 15, 2024 were 15.81M with a Short Ratio of 5.62, compared to 16.3M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.46% and a Short% of Float of 11.92%.
Earnings Estimates
There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.19, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.08 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.3 and -$0.57 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.48, with 7 analysts recommending between -$0.35 and -$0.63.
